Intrinsic value of Corcept Therapeutics - CORT

Previous Close

$12.52

  Intrinsic Value

$147.66

stock screener

  Rating & Target

str. buy

+999%

Previous close

$12.52

 
Intrinsic value

$147.66

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of CORT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  255
  394
  589
  854
  1,205
  1,656
  2,223
  2,919
  3,756
  4,745
  5,892
  7,203
  8,682
  10,330
  12,147
  14,129
  16,276
  18,583
  21,046
  23,662
  26,427
  29,339
  32,395
  35,594
  38,935
  42,419
  46,047
  49,822
  53,748
  57,827
Variable operating expenses, $m
  115
  178
  267
  387
  546
  750
  1,007
  1,322
  1,702
  2,149
  2,669
  3,263
  3,933
  4,680
  5,502
  6,401
  7,373
  8,418
  9,534
  10,719
  11,971
  13,290
  14,675
  16,124
  17,637
  19,216
  20,859
  22,570
  24,348
  26,196
Fixed operating expenses, $m
  36
  37
  37
  38
  39
  40
  41
  42
  43
  44
  44
  45
  46
  47
  49
  50
  51
  52
  53
  54
  55
  56
  58
  59
  60
  62
  63
  64
  66
  67
Total operating expenses, $m
  151
  215
  304
  425
  585
  790
  1,048
  1,364
  1,745
  2,193
  2,713
  3,308
  3,979
  4,727
  5,551
  6,451
  7,424
  8,470
  9,587
  10,773
  12,026
  13,346
  14,733
  16,183
  17,697
  19,278
  20,922
  22,634
  24,414
  26,263
Operating income, $m
  104
  179
  285
  429
  620
  866
  1,175
  1,555
  2,012
  2,552
  3,178
  3,895
  4,703
  5,603
  6,596
  7,679
  8,852
  10,113
  11,459
  12,889
  14,400
  15,992
  17,662
  19,411
  21,237
  23,142
  25,125
  27,188
  29,334
  31,564
EBITDA, $m
  104
  179
  285
  429
  620
  867
  1,176
  1,556
  2,014
  2,554
  3,181
  3,898
  4,706
  5,607
  6,601
  7,685
  8,859
  10,120
  11,468
  12,898
  14,411
  16,004
  17,675
  19,425
  21,253
  23,158
  25,143
  27,208
  29,356
  31,587
Interest expense (income), $m
  0
  0
  1
  2
  4
  7
  10
  15
  21
  28
  36
  46
  58
  71
  86
  102
  120
  140
  162
  185
  210
  236
  264
  293
  323
  355
  389
  424
  460
  498
  538
Earnings before tax, $m
  104
  178
  282
  425
  613
  856
  1,160
  1,534
  1,985
  2,516
  3,132
  3,837
  4,632
  5,518
  6,494
  7,559
  8,712
  9,951
  11,274
  12,679
  14,165
  15,728
  17,369
  19,087
  20,882
  22,752
  24,701
  26,728
  28,836
  31,027
Tax expense, $m
  28
  48
  76
  115
  166
  231
  313
  414
  536
  679
  846
  1,036
  1,251
  1,490
  1,753
  2,041
  2,352
  2,687
  3,044
  3,423
  3,824
  4,247
  4,690
  5,154
  5,638
  6,143
  6,669
  7,217
  7,786
  8,377
Net income, $m
  76
  130
  206
  310
  448
  625
  847
  1,120
  1,449
  1,836
  2,287
  2,801
  3,381
  4,028
  4,740
  5,518
  6,360
  7,264
  8,230
  9,256
  10,340
  11,482
  12,680
  13,934
  15,244
  16,609
  18,032
  19,511
  21,050
  22,649

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  259
  400
  598
  867
  1,223
  1,682
  2,257
  2,964
  3,814
  4,817
  5,982
  7,313
  8,815
  10,488
  12,332
  14,345
  16,524
  18,866
  21,366
  24,022
  26,829
  29,786
  32,888
  36,136
  39,528
  43,065
  46,748
  50,581
  54,566
  58,708
Adjusted assets (=assets-cash), $m
  259
  400
  598
  867
  1,223
  1,682
  2,257
  2,964
  3,814
  4,817
  5,982
  7,313
  8,815
  10,488
  12,332
  14,345
  16,524
  18,866
  21,366
  24,022
  26,829
  29,786
  32,888
  36,136
  39,528
  43,065
  46,748
  50,581
  54,566
  58,708
Revenue / Adjusted assets
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
  0.985
Average production assets, $m
  1
  1
  1
  2
  2
  3
  4
  6
  8
  9
  12
  14
  17
  21
  24
  28
  33
  37
  42
  47
  53
  59
  65
  71
  78
  85
  92
  100
  107
  116
Working capital, $m
  9
  15
  22
  32
  45
  61
  82
  108
  139
  176
  218
  267
  321
  382
  449
  523
  602
  688
  779
  875
  978
  1,086
  1,199
  1,317
  1,441
  1,569
  1,704
  1,843
  1,989
  2,140
Total debt, $m
  18
  44
  80
  129
  194
  278
  383
  513
  668
  852
  1,065
  1,309
  1,584
  1,890
  2,227
  2,595
  2,994
  3,423
  3,880
  4,366
  4,880
  5,421
  5,989
  6,583
  7,204
  7,851
  8,525
  9,227
  9,956
  10,714
Total liabilities, $m
  47
  73
  109
  159
  224
  308
  413
  542
  698
  881
  1,095
  1,338
  1,613
  1,919
  2,257
  2,625
  3,024
  3,452
  3,910
  4,396
  4,910
  5,451
  6,019
  6,613
  7,234
  7,881
  8,555
  9,256
  9,986
  10,744
Total equity, $m
  211
  326
  488
  708
  999
  1,374
  1,844
  2,421
  3,116
  3,935
  4,887
  5,975
  7,202
  8,568
  10,075
  11,720
  13,500
  15,413
  17,456
  19,626
  21,920
  24,335
  26,870
  29,523
  32,294
  35,184
  38,194
  41,325
  44,580
  47,964
Total liabilities and equity, $m
  258
  399
  597
  867
  1,223
  1,682
  2,257
  2,963
  3,814
  4,816
  5,982
  7,313
  8,815
  10,487
  12,332
  14,345
  16,524
  18,865
  21,366
  24,022
  26,830
  29,786
  32,889
  36,136
  39,528
  43,065
  46,749
  50,581
  54,566
  58,708
Debt-to-equity ratio
  0.080
  0.130
  0.160
  0.180
  0.190
  0.200
  0.210
  0.210
  0.210
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
Adjusted equity ratio
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817
  0.817

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  76
  130
  206
  310
  448
  625
  847
  1,120
  1,449
  1,836
  2,287
  2,801
  3,381
  4,028
  4,740
  5,518
  6,360
  7,264
  8,230
  9,256
  10,340
  11,482
  12,680
  13,934
  15,244
  16,609
  18,032
  19,511
  21,050
  22,649
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  1
  1
  1
  2
  2
  2
  3
  3
  4
  5
  6
  7
  7
  8
  9
  11
  12
  13
  14
  16
  17
  18
  20
  21
  23
Funds from operations, $m
  76
  130
  206
  310
  448
  625
  848
  1,121
  1,450
  1,838
  2,289
  2,804
  3,385
  4,032
  4,745
  5,524
  6,366
  7,272
  8,239
  9,265
  10,351
  11,493
  12,693
  13,948
  15,259
  16,626
  18,050
  19,531
  21,072
  22,673
Change in working capital, $m
  4
  5
  7
  10
  13
  17
  21
  26
  31
  37
  42
  49
  55
  61
  67
  73
  79
  85
  91
  97
  102
  108
  113
  118
  124
  129
  134
  140
  145
  151
Cash from operations, $m
  72
  125
  199
  300
  435
  609
  827
  1,096
  1,419
  1,802
  2,247
  2,756
  3,330
  3,971
  4,678
  5,450
  6,287
  7,186
  8,148
  9,169
  10,248
  11,386
  12,580
  13,830
  15,135
  16,497
  17,916
  19,392
  20,926
  22,522
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -7
  -8
  -9
  -11
  -12
  -13
  -14
  -16
  -17
  -18
  -20
  -21
New CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
Cash from investing activities, $m
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -6
  -8
  -9
  -10
  -12
  -12
  -13
  -15
  -17
  -18
  -19
  -21
  -23
  -24
  -26
  -28
  -29
Free cash flow, $m
  72
  124
  198
  300
  434
  607
  825
  1,093
  1,416
  1,798
  2,242
  2,751
  3,324
  3,964
  4,670
  5,442
  6,277
  7,175
  8,135
  9,155
  10,233
  11,369
  12,562
  13,810
  15,115
  16,475
  17,892
  19,366
  20,899
  22,492
Issuance/(repayment) of debt, $m
  18
  26
  36
  49
  65
  84
  105
  129
  156
  184
  213
  244
  275
  306
  337
  368
  399
  429
  458
  486
  514
  541
  568
  594
  621
  647
  674
  701
  729
  758
Issuance/(repurchase) of shares, $m
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  22
  26
  36
  49
  65
  84
  105
  129
  156
  184
  213
  244
  275
  306
  337
  368
  399
  429
  458
  486
  514
  541
  568
  594
  621
  647
  674
  701
  729
  758
Total cash flow (excl. dividends), $m
  94
  150
  235
  349
  499
  691
  931
  1,223
  1,572
  1,982
  2,455
  2,994
  3,599
  4,270
  5,008
  5,810
  6,676
  7,604
  8,593
  9,641
  10,747
  11,910
  13,130
  14,405
  15,735
  17,122
  18,566
  20,067
  21,628
  23,250
Retained Cash Flow (-), $m
  -79
  -115
  -162
  -220
  -291
  -375
  -470
  -577
  -694
  -820
  -951
  -1,088
  -1,227
  -1,367
  -1,507
  -1,645
  -1,780
  -1,913
  -2,043
  -2,170
  -2,294
  -2,415
  -2,535
  -2,653
  -2,771
  -2,890
  -3,009
  -3,131
  -3,256
  -3,384
Prev. year cash balance distribution, $m
  59
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  73
  35
  73
  129
  208
  317
  460
  645
  878
  1,162
  1,504
  1,906
  2,372
  2,904
  3,501
  4,165
  4,895
  5,691
  6,550
  7,471
  8,453
  9,495
  10,595
  11,751
  12,964
  14,232
  15,556
  16,936
  18,372
  19,866
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  70
  32
  64
  106
  161
  230
  311
  403
  504
  609
  714
  814
  902
  975
  1,028
  1,058
  1,065
  1,048
  1,008
  949
  874
  788
  694
  599
  504
  415
  334
  262
  201
  150
Current shareholders' claim on cash, %
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6
  99.6

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

FINANCIAL RATIOS  of  Corcept Therapeutics (CORT)

Valuation Ratios
P/E Ratio 176.4
Price to Sales 17.4
Price to Book 34.4
Price to Tangible Book
Price to Cash Flow 78.4
Price to Free Cash Flow 78.4
Growth Rates
Sales Growth Rate 62%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 36.6%
Interest Coverage 0
Management Effectiveness
Return On Assets 13.2%
Ret/ On Assets - 3 Yr. Avg. -21.3%
Return On Total Capital 15.7%
Ret/ On T. Cap. - 3 Yr. Avg. -23.7%
Return On Equity 26.7%
Return On Equity - 3 Yr. Avg. -130.9%
Asset Turnover 1.3
Profitability Ratios
Gross Margin 97.5%
Gross Margin - 3 Yr. Avg. 97.3%
EBITDA Margin 9.9%
EBITDA Margin - 3 Yr. Avg. -39%
Operating Margin 12.3%
Oper. Margin - 3 Yr. Avg. -31.9%
Pre-Tax Margin 9.9%
Pre-Tax Margin - 3 Yr. Avg. -39%
Net Profit Margin 9.9%
Net Profit Margin - 3 Yr. Avg. -39%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CORT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CORT stock intrinsic value calculation we used $159.201 million for the last fiscal year's total revenue generated by Corcept Therapeutics. The default revenue input number comes from 0001 income statement of Corcept Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CORT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CORT is calculated based on our internal credit rating of Corcept Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Corcept Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CORT stock the variable cost ratio is equal to 45.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $35 million in the base year in the intrinsic value calculation for CORT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Corcept Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Corcept Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CORT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CORT are equal to 0.2%.

Life of production assets of 3.4 years is the average useful life of capital assets used in Corcept Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CORT is equal to 3.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $190.968 million for Corcept Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 116.051 million for Corcept Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Corcept Therapeutics at the current share price and the inputted number of shares is $1.5 billion.

RELATED COMPANIES Price Int.Val. Rating
ALDR Alder BioPharm 13.18 1.03  str.sell
PFE Pfizer 43.52 34.10  hold
FOLD Amicus Therape 10.78 0.21  str.sell

COMPANY NEWS

▶ Corcept: 3Q Earnings Snapshot   [07:09PM  Associated Press]
▶ 8 Stocks Joel Greenblatt Continues to Buy   [Aug-30-18 06:04PM  GuruFocus.com]
▶ 3 High-Growth Stocks That Could Soar   [Aug-20-18 04:57PM  Motley Fool]
▶ Corcept: 2Q Earnings Snapshot   [05:26PM  Associated Press]
▶ Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list   [May-17-18 04:13PM  American City Business Journals]
▶ May Undervalued Stock Opportunities   [May-12-18 10:02AM  Simply Wall St.]
▶ Corcept: 1Q Earnings Snapshot   [May-08-18 06:55PM  Associated Press]
▶ 10 Healthcare Stocks to Stave Off the Market Flu   [Apr-06-18 02:23PM  InvestorPlace]
▶ Corcept misses 4Q profit forecasts   [Feb-22-18 06:31PM  Associated Press]
▶ Why Corcept Therapeutics Stock Gained 27.4% in January   [Feb-13-18 05:12PM  Motley Fool]
▶ These Biotech Stocks Each Dived More Than 20% Is The Sell-Off Overdone?   [Feb-05-18 04:30PM  Investor's Business Daily]
▶ Biotech Roundup: Who's Popping On Drug, Merger, Earnings News?   [Feb-01-18 04:02PM  Investor's Business Daily]
▶ Why Corcept Therapeutics Shares Climbed 10.8% Today   [Dec-21-17 05:20PM  Motley Fool]
▶ This Biotech Stock Launched After Joining The S&P 600 SmallCap   [04:15PM  Investor's Business Daily]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.